Qiagen N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QGEN research report →
Range $38.6 – $52
Price Chart
About the company
Qiagen N. V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
- CEO
- Jon Pratt
- IPO
- 1996
- Employees
- 5,400
- HQ
- Venlo, LI, NL
Get TickerSpark's AI analysis on QGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.18B
- P/E
- 26.68
- Fwd P/E
- 20.27
- PEG
- -49.90
- P/S
- 4.84
- P/B
- 2.95
- EV/EBITDA
- 15.72
- Div Yield
- 5.32%
- Gross Margin
- 62.45%
- Op Margin
- 26.21%
- Net Margin
- 18.19%
- ROE
- 11.04%
- ROIC
- 8.55%
Latest fiscal year · YoY change
- Revenue
- $2.09B+5.7%
- Gross Profit
- $1.29B+33.5%
- Op Income
- $520.31M
- Net Income
- $424.88M+408.3%
- EPS
- $2.04+423.1%
- OCF Growth
- -2.9%
- FCF Growth
- -10.5%
- 52W High
- $57.82
- 52W Low
- $32.53
- 50D MA
- $47.07
- 200D MA
- $42.40
- Beta
- 0.56
- RSI (14)
- 57
- Avg Volume
- 3.66M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Qiagen beat Q2 expectations on sales and EPS, held margins near 30%, and reaffirmed full-year guidance while pointing to a stronger second half driven by product launches and easing headwinds.· August 6, 2026
- Q2 net sales were $535 million, unchanged reported and at CER, beating the outlook for about a 2% CER decline.
- Adjusted diluted EPS was $0.62, above the outlook of at least $0.60 at CER.
- Adjusted operating income was $157 million, with a 29.4% margin versus 29.9% a year ago; adjusted gross margin was 66.2% versus 66.7%.
- Growth pillars grew 5% at CER, led by Sample Technologies, QIAcuity, QDI and a return to growth for QuantiFERON.
- Management reaffirmed 2026 guidance and expects sales growth to improve in the second half, helped by new launches and the end of NeuMoDx/DIALUNOX headwinds.
Qiagen reported Q2 2026 net sales of $535 million, flat year over year on both a reported basis and at CER, versus an outlook for about a 2% CER decline. Adjusted diluted EPS was $0.62, above the guidance of at least $0.60 at CER. Adjusted operating income was $157 million, down 2%, with adjusted operating margin of 29.4% versus 29.9% in Q2 2025; adjusted gross margin was 66.2% versus 66.7% a year ago. For the first half, operating cash flow was $301 million, unchanged from the same period of 2025, and days sales outstanding improved to about 55 days from about 57 days at the end of 2025. Full-year guidance was reaffirmed for total net sales growth of about 1% to 2% at CER and adjusted diluted EPS of at least $2.43 at CER. For Q3, management expects net sales growth of about 1% to 2% CER and adjusted diluted EPS of at least $0.62 at CER. Management also said tariff repayments could benefit full-year EPS by about $0.02 at CER net of customer refunds, and currency should add about 1 percentage point to full-year sales with neutral EPS impact.
Thierry Bernard said the quarter showed disciplined execution, resilience, and profitable growth above expectations. He emphasized that Sample Technologies, QIAcuity, and QDI are growing above market, QuantiFERON returned to growth, and new launches are supporting a stronger second half. He also framed the strategic review and CEO transition as separate but ongoing processes, saying Qiagen remains open to options that can improve long-term shareholder and stakeholder value.
Roland Sackers highlighted that profitability stayed high despite some gross margin pressure from product mix. He cited adjusted operating income of $157 million, a 29.4% margin, adjusted gross margin of 66.2%, and an 18% tax rate in line with the 17% to 18% target. He said first-half operating cash flow was $301 million, with roughly $20 million of cash payments for efficiency and restructuring programs and a planned inventory build, while the company also completed a $500 million synthetic share repurchase in January and paid a second annual dividend of around $72 million in July; the dividend per share rose 40% to $0.35 from $0.25 in 2025.
Analysts pressed on the second-half guidance, especially the implied acceleration from Q3 to Q4, and management pointed to the end of NeuMoDx/DIALUNOX headwinds, new launches, easier comps, and improving funding trends, while still sounding cautious on U.S. research funding. Questions on QuantiFERON focused on competition and the softer language around the $500 million target; management said the $35 million immigration-testing headwind is now removed from the base, competition has long existed, and the main goal remains converting more latent TB customers from skin tests to blood tests. Analysts also asked about the strategic review and capital deployment, and management said the review is continuous, while the lack of a second-quarter buyback was explained as a timing/technical issue around the post-AGM opposition period in Europe.
The call showed Qiagen can still beat guidance even in a mixed funding environment, with sales and EPS both ahead of plan and profitability staying near 30%. Management sounded confident that QIAcuity, Sample Technologies, QDI, QuantiFERON, and QIAstat can all accelerate in the second half as product launches gain traction and old portfolio headwinds fade.
Management repeatedly flagged caution around U.S. research and NIH funding, saying funding has improved sequentially but remains below 2025 levels year to date, which can affect instrument sales. QuantiFERON still faces the loss of immigration-testing revenue and QIAstat was pressured by a tough respiratory comparison, while Q3 guidance implies some near-term drag from those comparisons before the expected Q4 step-up.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 206.50M
- Float Shares
- 205.25M
of shares held by institutions
366 13F filers
Congressional trading
Senate and House stock disclosures for QGEN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Apr 13, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 14, 22 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jan 23, 19 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jan 9, 19 | Filing → |
| Peter WelchHouse · VT00 | Sell | Mar 24, 20 | Filing → |
| Peter WelchHouse · VT00 | Buy | Feb 27, 20 | Filing → |
| Alan LowenthalHouse · CA47 | Sell | Oct 8, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Sell | Oct 8, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Sell | Oct 8, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Buy | Sep 13, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Buy | Sep 13, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Buy | Sep 12, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Buy | Sep 12, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Buy | Sep 13, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Price T Rowe Associates Inc | 16.44M | ▲ 5.08M |
| Wellington Management Group Llp | 11.64M | ▼ 770.54K |
| Vanguard Group Inc | 9.54M | ▲ 118.14K |
| Principal Financial Group Inc | 8.40M | ▲ 1.75M |
| Vanguard Capital Management LLC | 6.26M | ▲ 46.26K |
| Blackrock, Inc. | 5.81M | ▼ 98.22K |
| Fivespan Partners, LP | 5.43M | ▲ 2.74M |
| Goldman Sachs Group Inc | 5.12M | ▲ 676.44K |
| Earnest Partners LLC | 4.65M | ▲ 78.84K |
| Amundi | 4.65M | ▲ 961.91K |
| Norges Bank | 4.33M | ▲ 4.33M |
| Bank Of America Corp | 3.77M | ▲ 774.88K |
Held by 158 ETFs
Biggest fund positions in QGEN by dollar value.
Our QGEN coverage
Recent articles, reports, and earnings notes.
Want a deeper read on QGEN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Interpreting Qiagen (QGEN) International Revenue Trends
zacks.com · Nov 13
Qiagen N.V. (QGEN) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com · Nov 6
QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director
businesswire.com · Nov 6
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 4
Qiagen (QGEN) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 4
QIAGEN Reports Full Q3 2026 Results
businesswire.com · Nov 4
Do Options Traders Know Something About Qiagen Stock We Don't?
zacks.com · Oct 31
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
